<DOC>
	<DOCNO>NCT00001398</DOCNO>
	<brief_summary>This trial , sponsor Amgen , Inc. , produce recombinant methionyl human stem cell factor ( r-metHuSCF ) , also involve two institution . The primary objective determination safety administer multiple dos r-metHuSCF setting acquire aplastic anemia evaluation effect r-metHuSCF peripheral blood count . Potential effect r-metHuSCF frequency need red cell platelet transfusion bone marrow morphology/cellularity also evaluate .</brief_summary>
	<brief_title>Stem Cell Factor Medication Aplastic Anemia</brief_title>
	<detailed_description>This trial , sponsor Amgen , Inc. , produce recombinant methionyl human stem cell factor ( r-metHuSCF ) , also involve two institution . The primary objective determination safety administer multiple dos r-metHuSCF setting acquire aplastic anemia evaluation effect r-metHuSCF peripheral blood count . Potential effect r-metHuSCF frequency need red cell platelet transfusion bone marrow morphology/cellularity also evaluate .</detailed_description>
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Anemia , Aplastic</mesh_term>
	<mesh_term>Pancytopenia</mesh_term>
	<criteria>Acquired moderate severe aplastic anemia . Intolerant , failure durably respond , ATG/ALG therapy without cyclosporin . Patients may receive ATG/ALG , therapy 12 week prior enrollment cyclosporin 4 week prior enrollment . Two year age old . Karnofsky Performance Status great equal 60 percent . Adequate organ function define serum creatine le 2.0 mg/dl bilirubin le 2.0 mg/dl . Patients ( parent [ ] /responsible guardian [ ] ) must able comprehend willing sign inform consent prior start rmetHuSCF therapy . No current diagnosis past history myelodysplastic syndrome . No diagnosis Fanconi 's anemia , dyskeratosis congenita , congenital form aplastic anemia . No current diagnosis clinically active paroxysmal nocturnal hemoglobinuria ( PNH ) define patient clinically significant thrombosis hemolysis . No diagnosis eosinophilic fasciitis . No treatment ATG , ALG , immunosuppresive agent within 12 week enrollment treatment cyclosporine A IL3 within 4 week enrollment . No treatment hematopoietic growth factor within 2 week enrollment . No evidence active uncontrolled infection . No known allergy Ecoliderived product . No current recent symptom asthma occur within past 10 year ( include allergic asthma , asthma induce cold temperature , infection , exercise ) . No history anaphylactic/anaphylactoidtype event manifest disseminated urticaria , laryngeal edema , and/or bronchospasm ( example : food , insect bite , etc ) . Patients drug allergy , manifest solely rash and/or urticaria , exclude . An isolated episode urticaria occur 3 year early contraindication . No significant nonmalignant disease include previously document HIV infection , uncontrolled hypertension ( diastolic blood pressure great 115 mmHg ) , unstable angina , congestive heart failure ( great NY Class II ) , poorly control diabetes , coronary angioplasty within 6 month , uncontrolled atrial ventricular cardiac arrhythmia . No pregnancy breast feeding . Those childbearing potential must observe adequate birth control measure . No treatment investigational agent ( hematopoietic growth factor ) within 4 week study entry . No concurrent use beta adrenergic block agent . No concurrent use , use within past 2 week , Monoamine Oxidase Inhibitors ( MAO Inhibitors ) . No psychiatric , addictive , disorder compromise ability give truly informed consent participation study .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2002</verification_date>
	<keyword>Hematopoiesis</keyword>
	<keyword>Stem Cell Cycling</keyword>
	<keyword>Bone Marrow Failure</keyword>
	<keyword>Acquired Aplastic Anemia</keyword>
</DOC>